+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years - 120Years
All Genders
ID03340129

Randomized Trial of Ipilimumab and Nivolumab With or Without Stereotactic Radiotherapy for Melanoma Brain Metastases

Led by Melanoma Institute Australia · Updated on 2026-10-08

218

Participants Needed

9

Research Sites

139 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the combination of immunotherapy drugs ipilimumab and nivolumab with or without concurrent stereotactic radiotherapy in patients who have asymptomatic, untreated melanoma brain metastases. This phase II randomized trial aims to compare these treatments to determine their effect on neurological death rate at 12 months and assess other outcomes such as tumor response, progression-free survival, overall survival, neurocognitive function, adverse events, and quality of life. The study builds on previous findings that combining these immunotherapies is more effective than nivolumab alone and investigates how radiotherapy might boost immune responses against tumors. Participants will receive ipilimumab and nivolumab at doses approved for advanced melanoma. One group will also receive stereotactic radiotherapy to brain metastases within seven days of a baseline MRI scan. Radiotherapy doses vary by lesion size and are delivered in one or several fractions. Both groups may receive salvage therapies like surgery or radiotherapy if brain disease progresses. Treatment is administered according to a 11 randomization with stratification by factors such as brain metastases count and mutation status. During participation, patients will undergo regular MRIs, neurocognitive tests using the Montreal Cognitive Assessment, neurological exams with the NANO scale, and quality of life questionnaires including FACT-Brain and EORTC modules. Blood, tissue, stool, and urine samples will be collected for biomarker analysis. Adverse events will be monitored closely, and continued treatment beyond progression may be allowed if clinically appropriate. The study plans long-term follow-up up to 10 years to track outcomes and safety, with total participation lasting up to the study completion in 2029.

CONDITIONS

Brief Title

Anti-PD 1 Brain Collaboration + Radiotherapy Extension (ABC-X Study)

Research Team

G

Georgina V Long, MBBS PhD

M

Maria Gonzalez, RN MHSc

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here